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Introduction
The aim of this research is to develop a blood test for autoantibodies that will determine whether a lung nodule discovered upon X-ray or CT is cancer. Our method is to first identify autoantibodies made by antigen stimulated, intratumoral B lymphocytes in patients with non-small cell lung cancer (NSCLC). These antibodies are then used to identify the stimulating antigens, and the antigens are used to formulate a diagnostic blood test for lung cancer.
Intratumoral B lymphocytes are associated with many types of cancer including NSCLC (1-3), breast cancer (4, 5) , and ovarian cancer (6) . Analysis of B cells from tumors and metastatic lymph nodes found hypermutated antibody genes and expansion of class switched memory cells and plasmablasts in patients with bladder cancer (7) . In addition, the presence of intratumoral germinal centers (GCs) have been reported in NSCLC (8, 9) , breast cancer (10-13), colon cancer (14) , and germ cell cancers (15) . In NSCLC, GCs are associated with early stage over late stage disease, suggesting a humoral immune response may hold these tumors in check (9) .
Further characterization of antigen stimulated intratumoral B cells and identification of tumor antigens might be exploited for diagnostic or therapeutic purposes. As described in our Annual Report, we identified antibodies to tropomyosin 4 (TPM4) expressed by an intratumoral B cell of one lung cancer patient, confirmed the presence of the antibody in this patient's serum, and then performed a pilot study to determine if the serum autoantibody could be used as a diagnostic biomarker for lung cancer. Although promising, the TPM4 and other antibodies isolated at the same time were polyreactive, suggesting an absence of antigen stimulated clonal expansion in the ITLs we isolated. The current work employs deep sequencing in an attempt to identify clonal populations of ITLs for recombinant antibody production with the aim of increasing the likelihood of identifying antibodies against tumor antigens.
Body

Materials and Methods
Patients
The current study was approved by our Institutional Review Board and all patients signed an informed consent prior to enrollment in the study. Intratumoral lymphocytes (ITLs) used in this study were isolated from freshly resected NSCLC tissue from seven patients undergoing surgery at Duke University Medical Center. Patient demographics are shown in Table I .
B Cell Isolation and FACS
We isolated ITLs from lung tumor specimens by first placing the tissue in a Petri dish containing RPMI-1640 medium supplemented with 20 mM HEPES (RPMI/HEPES) and teasing the tissue into very small fragments with an 18 gauge needle. We then filtered the tissue fragment suspension sequentially through 100 µm and 40 µm pore-size nylon membranes and pelleted the cells by centrifugation for 10 min at 400 x g at 18°C. We resuspended the cell pellet in 2 ml RPMI/HEPES and isolated the lymphocytes over a Ficoll-Paque Plus (GE Healthcare, Uppsala, Sweden) cushion according to the manufacturer's instructions. We resuspended the final lymphocyte pellet in Bambanker (Wako Chemicals, Richmond, VA) cell freezing medium and stored the cells at -80°C until FACS.
Prior to deep sequencing, thawed ITLs from each patient were first divided into approximately equal portions. One portion was used for DNA and RNA isolation and the other portion sorted as described below (Table 2 ).
For sorting of memory B cells and plasma cells, we washed the ITLs in PBS and stained them with Aqua vital dye (Invitrogen, Carlsbad, CA) and the following anti-human antibodies: CD3 phycoerythrin (PE)-Cy5, CD14 PE-Cy5, CD16 PE-Cy5, CD235a PE-Cy5, CD45 PE-Texas Red, CD19 allophycocyanin (APC)-Cy7, CD27 PE-Cy7, CD38 APC-Cy5. 5 
Deep Sequencing
Results
Sorting of B cells from ITLs
In order to use deep sequencing as a means to identify clonally expanded B cells, with the aim of using this information to select specific B cells for recombinant antibody production, there had to be a way to access individual cells after the sequencing analysis. We accomplished this by dividing the ITL samples into two approximately equal aliquots, using one aliquot for sequencing and the other for fluorescence activated cell sorting (FACS) of individual B cells. Once sequences demonstrating oligoclonality were identified by sequencing B cells en masse, we could then go back to the sorted cells and sequence the VH and VL Ig genes from the individual cells. We would then prepare recombinant antibodies only from those cells whose VH and VL sequences placed them in the same clone(s) as those identified in the bulk sequencing analyses.
Details of the ITL samples used for sorting and DNA/RNA preps are shown in Table 2 .
Deep Sequencing
We isolated and sorted ITLs from seven additional lung cancer patients as described above and subjected them to deep sequencing of Ig VH and VL genes.
Discussion
Tumor growth reflects a dynamic, multidimensional relationship between cancer cells and host cells, including stromal, endothelial, and immune cells (20, 21) . Tumors can be infiltrated with many types of lymphocytes, some that may foster and others that may inhibit tumor growth and progression (22) . GCs, normally found in secondary lymphoid organs such as the spleen and lymph nodes, can also develop in tumors. GCs are well-defined loci of B cells, T cells and dendritic cells in which B cells proliferate and undergo differentiation, somatic hypermutation and affinity maturation (23) . The presence of GCs in tumors is consistent with an in situ immune response to tumor antigens. We aimed to develop a method to identify the targets of antibodies produced by intratumoral B cells. This would allow us to explore the possibility that tumor antigens targeted by these intratumoral B cells may be relevant therapeutic targets or that the antibodies they produce may be diagnostic biomarkers. (See our Annual Report for additional information.)
In our Annual Report, we described how we used methodology originally developed to study the role of antigen in the progression of chronic lymphocytic leukemia (27) and later modified by researchers in the HIV field to permit the cloning of human antibodies from antigen-secreting B cells (17, 28) . This study represented the first attempt to adapt this methodology to characterize single B cells isolated from a solid tumor and to identify their stimulating antigens. Although our results were promising and instructive, all of the recombinant antibodies that we produced from ITLs were polyreactive. Polyreactive antibodies are antibodies of low affinity (Kd of 10 -3 -10 -7 M) that react with a variety of totally unrelated antigens (18).
In newborns, 50% of cord B cells express polyreactive antibodies (32) and in adults, 15-20% of peripheral B cells express polyreactive antibodies (18). Interestingly, polyreactive antibodies in the circulation appear to have broad antimicrobial properties (33) . It is intriguing to speculate that polyreactive antibodies in tumors may, in the aggregate, have antitumor properties. It is also possible, however, that the ITLs used for antibody production were present in the intratumoral space due to the presence of peripheral blood in the tumor vessels. In an attempt to improve our chances of isolating ITLs arising from antigen stimulated clonal expansion, our most recent work employed deep sequencing to identify those ITLs that have undergone clonal expansion and affinity maturation. We reasoned that since the VH and VL Ig gene sequences of polyreactive antibodies resemble germline antibodies, deep sequence analysis could distinguish monospecific from polyreactive antibodies expressed by intratumoral B cells.
This analysis identified a total of 155,901 functional VH gene sequences with individual patient samples containing from 3,327 to 77,182 functional sequences (Table 3) . Sequences representing all VH gene families were identified and exhibited a distribution typically found in peripheral B cells. No dominant clones were identified.
Key Research Accomplishments
 Developed a method to quantify the distribution of VH gene families in ITLs using deep sequencing.
 Although no dominant clones were identified, the highly detailed characterization of ITL immunoglobulins provided by this analysis shows that this method can be an effective means of elucidating the humoral response within tumors.
 Using microdissected intratumoral GCs as a source of ITLs for VH and VL Ig gene sequencing may be a more effective starting point for identifying tumor associated antibodies for diagnostics and tumor associated antigens for therapeutics.
Reportable Outcomes
Manuscript submitted for publication (under review) -Interrogation of Intratumoral B Lymphocytes for the Discovery of Novel Molecular Targets
Conclusions
The intratumoral space can be a rich source of information relating to the host immunological response to malignancy. As described in our Annual Report, we produced recombinant human antibodies from several ITLs isolated from freshly resected NSCLC tumors. Although all of these antibodies were polyreactive, one antibody demonstrated a preference for TPM4 and showed some selectivity as a diagnostic marker for lung cancer. This study provided the impetus for developing a method that would allow a more focused approach to identify intratumoral B cells responding to stimulation by tumor-associated antigens. Although we were successful in developing a robust deep sequencing protocol to characterize ITL VH and VL gene sequences, we were unable to identify oligoclonal B cells. Hence, the next iteration of our protocol will be to focus on the deep sequencing of ITLs residing in intratumoral germinal centers (GCs). As we have reported (ref), GCs arise in tumors due to antigen stimulation and are more prevalent in early stage tumors. This suggests that the stimulating antigens responsible for intratumoral GCs may be important in a successful host anti-tumor immune response. Identifying clonally expanded B cells from these GCs will allow us to produce the associated antibodies, and identify the antigens to which these antibodies bind. Further studies will determine the utility of the antigens as therapeutic targets, and whether the antibodies can be used in therapeutic strategies. Alternatively, the antibodies may be useful as diagnostic agents. 
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